IM156
Phase 1Small molecule
IM156 is one of 64 small molecule programs targeting Lymphoma. It is currently in Phase 1.
3
Indications
2
Total Trials
1
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Blenoxane
SSequus Pharmaceuticals
Preclinical
Oncaspar
SServier
Preclinical
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
PEG-Intron
Merck & Co.Preclinical
IM156
IImmunoMet Therapeutics, Inc.
Phase 1
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Stem Cells
KKang Stem Biotech Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IM156. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- IImmunoMet Therapeutics, Inc.